衰弱、多重用药、减药与23小时活动:小鼠模型的启示
该临床前研究以老年雄性C57BL/6J小鼠为对象,探讨不同慢性用药方案(多重用药与单药治疗)及减药对日常活动的影响,并分析其与衰弱及衰弱轨迹的关系。研究发现,药物负担指数(DBI)升高的多重用药会显著改变活动,且不能从单药反应外推;减药后部分药物效应可逆、部分不可逆,并观察到新变化。不同干预组衰弱与行为学结局的相关性独特,共识别出四个具有不同衰弱轨迹和特征的聚类。
要点
- 多重用药且DBI升高会显著改变老年小鼠活动,不能由单药反应外推。
- 减药后部分药物效应可逆、部分不可逆,并出现新变化。
- 不同用药干预组的衰弱与行为学结局相关性独特,识别出四个衰弱轨迹聚类。
核心结论
- 用药与减药可影响活动、衰弱及衰弱轨迹,多重用药与减药背景是临床前衰弱研究转化的重要考量。
研究设计与样本
- 使用老年雄性C57BL/6J(B6)小鼠的临床前研究,12月龄起慢性给予对照饮食、5种单药饮食之一或3种多重用药饮食(DBI递增),21月龄分层继续治疗或逐渐减药,24月龄用LABORAS自动行为识别系统评估23小时活动。
主要发现
- DBI升高的多重用药显著改变活动,且不能从单药反应外推。
- 减药后部分药物效应可逆、部分不可逆,并观察到新变化。
- 各干预组衰弱与LABORAS行为结局的相关性独特,识别出四个具有不同衰弱轨迹、特征、缺陷和行为结局的聚类。
临床怎么用
- 老年衰弱患者的多重用药管理需考虑药物负担对活动与衰弱轨迹的潜在影响,减药效应可能部分可逆、部分不可逆。
局限性
- 为临床前动物研究,结论向老年人群转化需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of older people with frailty commonly includes polypharmacy and deprescribing. The impacts of frailty on the outcomes of medication use and deprescribing are poorly understood, as are the effects of medication use and deprescribing on frailty and function. Here, using aged C57BL/6J (B6) male mice, we explore the effects of different chronic drug regimens (polypharmacy and monotherapy) and deprescribing on daily activities using an automated behavioral recognition cage and explore the relationship with frailty and trajectories. At 12 months, male C57BL/6 mice were chronically administered a control diet, 1 of 5 monotherapy diets, or 1 of 3 polypharmacy diets with an increasing Drug Burden Index (measure of total exposure to sedative and anticholinergic medications). At 21 months of age, mice were stratified to continue treatment or to have treatment gradually withdrawn (deprescribed). At 24 months, mice were assessed using the Laboratory Animal Behavior Observation Registration and Analysis System (LABORAS) automated animal behavioral recognition system for 23 hours. We found that polypharmacy with increasing DBI substantially altered activity and could not be extrapolated from monotherapy response. After deprescribing, while some of the drug effects were reversible, others were irreversible, and we observed some novel changes. Exploring the relationship between frailty and LABORAS behavioral outcomes revealed unique correlations for each intervention group. Four key clusters were identified with different frailty trajectories and attributes, deficits, and LABORAS outcomes. This preclinical study demonstrates that medication use and deprescribing can impact activity, frailty, and frailty trajectories. The context of polypharmacy and deprescribing are important considerations to enhance translation of preclinical studies of frailty.
引用
- Mach J, Winardi K, Hilmer SN, et al. Frailty, polypharmacy, deprescribing, and 23-hour activity: insights from a mouse model. J Gerontol A Biol Sci Med Sci. 2026. PMID: 42391622. doi:10.1093/gerona/glag170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。